Life Length is an industry-leading biotechnology company working to improve people’s health and lifestyle worldwide installed in Fundación Parque Científico de Madrid (FPCM) since 2014. After many years of work, they have positioned their technology at the forefront of the telomere measurement and diagnostics field.
They have developed a unique and proprietary high-throughput technology. Robust, sensitive and reproducible, it can be combined with other tests to provide a comprehensive picture of an individual’s overall health and aging process.
The company offers testing services to physicians and individuals, researchers and corporations across many industries, developing the adoption of telomeres and telomerase activity as key health biomarkers, advancing towards better and longer lifespans.
Faced with this major financial challenge, Life Length turned to the Enterprise Europe Network for help. Local Network members based in Fundación Parque Científico de Madrid (FPCM), and Fundación para el Conocimiento madri+d, have provided support to Life Length since 2014 and were ready to advise and assist Life Length in applying for the EU’s Horizon 2020 SME Instrument, a programme designed to help innovative small firms with high growth potential.
The Network advisers ensured Life Length’s application was both convincing and complete, which led to the SME securing EUR 3.1 million for its ONCOCHECK project. It will now carry out clinical studies involving 32 hospitals and over 4,000 individuals to support the development of preventive treatments for lung, prostate, solid tumours, leukaemia and other cancers.
The strong clinical results of the prostate cancer study have evolved into ProsTAV™, a new tool designed to improve the current prostate cancer diagnosis protocol by significantly reducing the number of unnecessary biopsies.
ProsTAV™ is a state-of-the-art prostate cancer risk-score biomarker developed by Life Length with their proprietary Telomere Analysis Technology® (TAT®) methodology. ProsTAV™, together with the current screening protocol, can save hundreds of thousands of men annually from undergoing unnecessary biopsies as well as enormous savings – hundreds of millions of dollars per year.
*Credits to #SomosFPCM #EENCanHelp for this fantastic video.
